ArticleBMC pharmacology & toxicology2025
Cardioprotective effects of carvacrol in the isoproterenol-induced myocardial infarction model.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Protective Effect of Carvacrol Against Isoproterenol-Induced Cardiotoxicity in Rats.Medeniyet medical journal · 2026Article
- Eugenol attenuates paclitaxel-induced cardiotoxicity by modulating autophagy-related markers in rats.Iranian journal of basic medical sciences · 2026Article
- The Role of the Gut Microbiota in Vascular Physiology and Health.International journal of molecular sciences · 2025Review
- Natural terpenoids with therapeutic potential against pulmonary arterial hypertension.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCardiovascular diseases are significant health problems that cause high mortality rates worldwide. Myocardial infarction (MI), in particular, is one of the leading conditions among these diseases. The aim of this study is to evaluate the potential therapeutic approach of carvacrol in the treatment of cardiovascular diseases by investigating its protective effects against myocardial infarction through oxidative stress and biomarker levels. MATERIALS AND
methodsIn this study, 28 male Wistar albino rats were used, and divided into 4 groups: Control, Carvacrol, Myocardial Infarction (MI), and MI + Carvacrol. Carvacrol was administered at a dose of 50 mg/kg for six weeks. The induction of MI was performed during the last 2 days of carvacrol administration by administering 100 mg/kg isoproterenol subcutaneously. At the end of the experiment, blood pressure, biomarkers such as troponin T, BNP, GDF-15, and IL-6 were measured, and cardiac tissue was histopathologically examined.
resultsThe results show that in the MI group, troponin T, BNP, IL-6 and GDF-15 levels were increased, while diastolic blood pressure and heart rate were decreased. In the carvacrol-treated group, troponin T, BNP, IL-6 and GDF-15 levels were decreased. Carvacrol did not significantly affect systolic, diastolic, mean arterial pressure, or heart rate in experimental groups. Moreover, carvacrol decreased necrosis, edema, and mononuclear cell infiltration in the heart tissue, which were increased due to MI.
conclusionIn conclusion, carvacrol demonstrated protective effects against myocardial infarction. Carvacrol alleviated histopathological damage by reducing inflammatory biomarkers. In addition to carvacrol improved troponin T and BNP markers.These findings suggest that carvacrol may be a promising agent in the treatment of cardiovascular diseases. However, more comprehensive and long-term studies are needed to confirm this effect and transfer it to clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.